Overview of the clinical efficacy of investigational anticancer drugs.
The purpose of this overview was to make a broad inventory of investigational drugs for medicinal cancer treatment and, specifically, to indicate the evidence of clinical efficacy. Information was retrieved from electronic database searches in Medline and CANCERLIT and relevant published reviews. As the most recent findings are first reported as conference abstracts, an important basis for identification of new drugs and clinical results was a hand search of 13,392 abstracts from five major recent cancer conferences. A total of 209 investigational approaches or drugs were identified and classified into one of eight groups according to proposed mechanism of action. For 28 drugs/approaches survival data were available from randomized controlled trials. Statistically significant benefit was observed for only 12. In earlier phases no or modest anticancer activity was reported. It is speculated that the expanding knowledge in tumour biology might not easily translate into new substantially better anticancer drugs.
Nygren
P
P
Department of Oncology, Radiology and Clinical Immunology, Section of Oncology University Hospital, Uppsala, Sweden. peter.nygren@medsci.uu.se
Larsson
R
R
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D015195:Drug Design; D015507:Drugs, Investigational / Q000627:therapeutic use*; D015870:Gene Expression; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects; D013678:Technology, Pharmaceutical
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015507:Drugs, Investigational